Recombinant Human B-cell Receptor CD22/Siglec-2/CD22 (C-6His) Biotinylated

Active protein: YES.

Activity: Loaded Biotinylated Human Siglec-2-His-Avi(Cat#CY36) on HIS1K Biosensor, can bind Anti-Human Siglec-2 mAb-Fc(Cat#NC013) with an affinity constant of 0.16 nM as determined in BLI assay.

Protein Construction: Biotinylated Recombinant Human B-cell Receptor CD22 is produced by our Mammalian expression system and the target gene encoding Asp20-Arg687 is expressed with a 6His, Avi tag at the C-terminus.

Sequence: Asp20-Arg687.

Fusion tag: C-6His-Avi.

Accession: P20273.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Mol Mass: 78 kDa.

AP Mol Mass: 110-130 kDa.

Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Background: Siglecs (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains. Human Siglec-2, also known as B-cell antigen CD22 or B-lymphocyte cell adhesion molecule (BL-CAM), is a B-cell restricted glycoprotein that is expressed in the cytoplasm of progenitor B and pre-B cells and on the surface of mature B cells. Two distinct human Siglec-2/CD22 cDNAs that arise from differential RNA processing of the same gene have been isolated. Siglec-2/CD22 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (cis) or adjacent (trans) cells. Interaction of CD22 with trans ligands on opposing cells was found to be favored over the binding of ligands in cis.

• Artikelnummer: ELSPKSH033956-100
• Hersteller: Elabscience Biotechnology
• Hersteller Artikelnummer: ELA-PKSH033956-100
• Green Labware: Nein
• Verpackungseinheit: 100 µg
• Mengeneinheit: STK
• Reaktivität: Human
• Methode: BLI Binding Assay
• Wirt: Human